There are limited data about the cost-effectiveness of therapy in<unk>  puberty. The main part of the economic burden of<unk>  puberty is because of various non-specific and specific blood tests, such as hormone assay. The main treatment for the patients with short stature is growth hormone (GH). The potential cost of treating all eligible children with growth hormone (GH) is approximately $40 billion dollars.
Delayed puberty cost-effectiveness of therapy
Hirsutism cost-effectiveness of therapy
Menopause cost-effectiveness of therapy
Delayed puberty secondary prevention
Androgen insensitivity syndrome primary prevention
Adiposogenital dystrophy cost-effectiveness of therapy
Delayed puberty risk factors
Adiposogenital dystrophy future or investigational therapies